Seminars in Oncology

Papers
(The median citation count of Seminars in Oncology is 1. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-02-01 to 2025-02-01.)
ArticleCitations
TOC163
TOC53
The likelihood of being helped or harmed obtained from clinical trial results for cancer therapy: Can it really help?41
Masthead34
Editorial Board26
Incidence of COVID-19 in outpatients with cancer receiving active treatment in the context of a pandemic: An Andalusian cohort study19
Breast cancer care: Looking for the new normal17
A narrative review of the principal glucocorticoids employed in cancer14
Communication strategies during the COVID-19 pandemic: Unforeseen opportunities and drawbacks13
Two decades of research toward the treatment of locally advanced and metastatic pancreatic cancer: Remarkable effort and limited gain13
Maintenance or consolidation therapy in small-cell lung cancer: an updated systematic review and meta-analysis.13
Pancreatic ductal adenocarcinoma in the era of precision medicine13
TOC12
Lung Cancer Screening and Precision Oncology12
Masthead12
Airway disorders associated with immune checkpoint inhibitor therapy: Two case reports and a systematic review11
Can locally developed me-too drugs aid price negotiation? An example of cancer therapies from China10
Successful restoration of checkpoint inhibitors efficacy after allogeneic hematopoietic cell transplant for classic Hodgkin lymphoma patients10
Editorial Board9
Seminars in oncology 50th anniversary9
Assessing Outcomes in NSCLC: Radiomic analysis, kinetic analysis and circulating tumor DNA9
Hepatitis B Virus Reactivation in Cancer Patients Receiving Chemotherapy—A Systematic Review and Meta-Analysis8
Primary adrenal insufficiency induced by immune checkpoint inhibitors: biological, clinical, and radiological aspects8
PARP inhibitors for prostate cancer8
Current and prospective antibody-based therapies in multiple myeloma8
Battling chronic myeloid leukemia in a resource-constrained country: A case of public-private partnerships7
KRAS mutation in pancreatic cancer7
Editorial Board7
Adenocarcinoma of the Pancreas: Past, Present, Future7
Molecular biomarkers and liquid biopsies in lung cancer7
Editorial Board6
Efficacy of metformin drug in preventing metabolic syndrome associated with androgen deprivation therapy (ADT) in prostate cancer patients: A systematic review and meta-analysis6
outside front cover6
outside front cover6
Masthead6
Outside front cover6
outside front cover6
Military exposures and lung cancer in United States Veterans6
Deciphering the US Regulatory Framework: Comparison Between Oncology Biosimilars and Reference Biologics6
Table of Contents5
Isolated lung metastases from pancreatic ductal adenocarcinoma (PDAC): Diagnostic and therapeutic challenges of a different disease5
Global distribution of prophylactic total gastrectomy in E-cadherin (CDH1) mutations5
NTRK fusion-positive cancer in nonagenarian patient. The importance of comprehensive geriatric assessment in older people for the inclusion in clinical trials5
Masthead5
Masthead5
Role of neoadjuvant pembrolizumab in advanced melanoma5
From doctors to ancillary staff: Regional and metropolitan cancer workforce perceptions and distress resulting from COVID-19 pandemic adaptations5
CAR T-cell therapy: A collaboration between authorized treatment centers and community oncologists5
outside front cover4
Torticollis as a presenting symptom of pediatric CNS tumors: A systematic review4
Influence of Cancer on COVID-19 Incidence, Outcomes, and Vaccine Effectiveness: A Prospective Cohort Study of U.S. Veterans4
Predictors of treatment refusal in patients with colorectal cancer: A systematic review4
Improving the efficacy of immunotherapy in small cell lung cancer: Leveraging recent scientific discoveries and tumor-specific antigens4
Editorial Board4
Efficacy of memantine in preventing neurocognitive dysfunction induced by radiation therapy in patients with brain metastases: A systematic review of clinical trials4
Challenges in initiating a lung cancer screening program: Experiences from two VA medical centers4
Future of immunotherapy in pancreas cancer and the trials, tribulations and successes thus far4
COVID-19 vaccine-related axillary lymphadenopathy in breast cancer patients: Case series with a review of literature4
Which future for de-intensified treatments in HPV-related oropharyngeal carcinoma?3
Radiation recall dermatitis: A review of the literature3
Lung cancer screening at the VA: Past, present and future3
Examining health related quality of life outcomes in multiple myeloma: Past and future perspectives3
outside front cover3
Editorial Board3
Impact of CT screening in lung cancer: Scientific evidence and literature review3
The heterogeneity of Epithelioid Hemangioendothelioma (EHE): A case series and review of the literature with emphasis on treatment options3
TOC3
The psychosocial and emotional experiences of cancer patients during the COVID-19 pandemic: A systematic review3
Current perspectives, guiding lights to the future, and transforming care for patients with multiple myeloma3
Cancer-specific mortality in patients with non-metastatic renal cell carcinoma who have undergone a nephrectomy and are eligible for adjuvant pembrolizumab3
Synchronous or metachronous presentation of pancreatic neuroendocrine tumor versus secondary lesion to pancreas in patients affected by renal cell carcinoma. Systematic review3
Editorial Board3
Editorial Board3
Irreversible electroporation of locally advanced pancreatic cancer2
Scoping to analyze oncology trial participation in Australia2
Inherited predisposition to pancreatic cancer2
Skin metastases in the clinical and dermoscopic aspects2
Real-world experience with CDK4-6 inhibition in the old and oldest old with a diagnosis of breast cancer2
outside front cover2
Modern radiographic imaging in multiple myeloma, what is the minimum requirement?2
Cancer diagnosis in Brazil in the COVID-19 era2
Is the neutrophil-to-lymphocyte ratio a prognostic factor in non-small cell lung cancer patients who receive adjuvant chemotherapy?2
Targeting EZH2 to overcome the resistance to immunotherapy in lung cancer2
Editorial Board2
Adverse events of different chemotherapy regimens in the first-line treatment of patients with advanced or metastatic urothelial cancer: A systematic review and network meta-analysis of randomized con2
Prevalence, mutational spectrum and clinical implications of clonal hematopoiesis of indeterminate potential in plasma cell dyscrasias2
PARP inhibitors: A review of the pharmacology, pharmacokinetics, and pharmacogenetics1
Masthead1
Importance, relevance, and pertinence of discussing mental health in the uro-oncology patient1
Epidemiology and genetics of early onset colorectal cancer—African overview with a focus on Ethiopia1
Liquid Biopsy, the hype vs. hope in molecular and clinical oncology1
Editorial Board1
TOC1
Improved outcomes in women with BRAF-mutant melanoma treated with BRAF/MEK-targeted therapy across randomized clinical trials. A systematic review and meta-analysis1
Colorectal cancer in Ethiopia: Epidemiological trends, diagnostic and laboratory capacities, and challenges1
Managing multiple myeloma in a resource-limited region: Diagnosis and treatment in Armenia1
Radiotherapy for locally advanced pancreatic ductal adenocarcinoma1
Analysis of actionable genetic alterations in lung carcinoma from the VA National Precision Oncology Program1
Editorial Board1
Adenocarcinoma on retrorectal cystic hamartoma: An illustrative image for a very rare diagnosis1
Defining genomic events involved in the evolutionary trajectories of myeloma and its precursor conditions1
Masthead1
Under-representation of women in Randomized Clinical Trials testing anticancer immunotherapy may undermine female patients care. A call to action1
Novel targeted therapies for advanced non-small lung cancer1
COVID 19 pandemic testing time – Crisis or opportunity in disguise for India?1
Treating advanced lung cancer in older Veterans with comorbid conditions and frailty1
PARP1 roles in DNA repair and DNA replication: The basi(c)s of PARP inhibitor efficacy and resistance1
0.054293870925903